VivoSeq
Neurology

Residual Neuromuscular Block

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Residual Neuromuscular Block is an early-stage landscape with 2 programs across 2 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

PreclinicalMerck & Co. logo

Merck & Co.

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

Sugammadex

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Neostigmine

Merck & Co.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Unknown status2 · 25%
Withdrawn1 · 13%
Recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function After Thoracoscopic Lung Resection: A Multicenter, Randomized, Double-Blind, Controlled Trial
Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Preclinical·NCT07309393·240 enrolled
Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
Completed·MMayo Clinic·Phase 4·NCT02728726·260 enrolled
Sugammadex and Neostigmine at Residual Neuromuscular Blockade
Completed·TTechnical University of Munich·N/A·NCT01006720·99 enrolled
Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine
Completed·GGuangzhou General Hospital of Guangzhou Military Command·N/A·NCT03656614·121 enrolled
Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery
Completed·SSeoul National University Bundang Hospital·N/A·NCT03292965·80 enrolled
Residual Neuromuscular Blockade in Cardiac Surgery Patients
Withdrawn·HHenry Ford Health System·Phase 4·NCT03574337
Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex
Unknown status·SSeoul National University Hospital·N/A·NCT05760560·52 enrolled
Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT04965532·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)